Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGES2 | Q9H7Z7 | 7/20 | 0.48 |
| ▸ | ITGAV | P06756 | 2/20 | 0.47 |
| ▸ | SLC1A3 | P43003 | 2/20 | 0.46 |
| ▸ | SLC1A2 | P43004 | 2/20 | 0.46 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.46 |
| ▸ | PGR | P06401 | 1/20 | 0.45 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.42 |
| ▸ | ACLY | P53396 | 2/20 | 0.41 |
| ▸ | MCOLN3 | Q8TDD5 | 1/20 | 0.40 |
| ▸ | CNR1 | P21554 | 1/20 | 0.40 |
| ▸ | CNR2 | P34972 | 1/20 | 0.40 |
| ▸ | CCR4 | P51679 | 1/20 | 0.38 |
| ▸ | SLC40A1 | Q9NP59 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31702015 | 0.79 | SLC1A3 (0.58) | SLC1A3SLC1A2SLC1A1PGRACLY | |
| SCHEMBL24541901 | 0.79 | SLC1A3 (0.58) | SLC1A3SLC1A2SLC1A1PGRACLY | |
| SCHEMBL810061 | 0.79 | SLC1A3 (0.58) | SLC1A3SLC1A2SLC1A1PGRACLY | |
| SCHEMBL985808 | 0.79 | SLC1A3 (0.58) | SLC1A3SLC1A2SLC1A1PGRACLY | |
| SCHEMBL3232763 | 0.78 | SLC1A3 (0.56) | ITGAVSLC1A3SLC1A2SLC1A1 | |
| SCHEMBL7646219 | 0.78 | SLC1A3 (0.56) | ITGAVSLC1A3SLC1A2SLC1A1 | |
| SCHEMBL14455227 | 0.78 | SLC1A3 (0.40) | SLC1A3SLC1A2SLC1A1ACLY | |
| SCHEMBL7526406 | 0.78 | SLC1A3 (0.56) | ITGAVSLC1A3SLC1A2SLC1A1 | |
| SCHEMBL7613315 | 0.77 | SLC1A3 (0.55) | ITGAVSLC1A3SLC1A2SLC1A1 | |
| SCHEMBL810628 | 0.76 | ACLY (0.46) | ITGAVSLC1A3SLC1A2PGRNR3C1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2399895-B1 | Process for producing optically active aliphatic fluoroalcohol | KANTO KAGAKU (JP) | 2018-08-08 | — | — | EP | disclosed |
| US-8558033-B2 | Process for producing optically active aliphatic fluoroalcohol | KANTO KAGAKU KABUSHIKI KAISHA (JP) | 2013-10-15 | — | — | US | disclosed |
| US-20110319671-A1 | PROCESS FOR PRODUCING OPTICALLY ACTIVE ALIPHATIC FLUOROALCOHOL | KANTO KAGAKU KABUSHIKI KAISHA (JP) | 2011-12-29 | — | — | US | disclosed |
| EP-2399895-A2 | Process for producing optically active aliphatic fluoroalcohol | Kanto Kagaku Kabushiki Kaisha (JP) | 2011-12-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110319671-A1 | PROCESS FOR PRODUCING OPTICALLY ACTIVE ALIPHATIC FLUOROALCOHOL | ADH1A, ADH1C, ADH5 | PTGES2 3252/4885ITGAV 1273/4885SLC1A3 2827/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.